{"filings":[{"id":1914282,"accession_number":"0000019584-26-000018","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-07-28T20:30:32+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 2026: adj. EPS $6.06 (+41.9%), VITAS EBITDA +20.6%, guidance raised to $25.00-$25.75","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $673.3M (+8.8% YoY); GAAP diluted EPS $5.13 (+43.7%); adjusted diluted EPS $6.06 (+41.9%).","VITAS net patient revenue $443.3M (+11.9%), ADC 23,687 (+6.1%), admissions +9.0%; adjusted EBITDA $80.6M (+20.6%).","Roto-Rooter revenue $229.9M (+3.3%), adjusted EBITDA $48.5M (flat), margin 21.1% (-77 bps).","Full-year 2026 adjusted EPS guidance raised to $25.00-$25.75 from $24.00-$24.75; mid-point +17.8% YoY.","Repurchased 210,000 shares for $89.8M in Q2; trailing 12-month repurchases reduced shares by ~10.5%."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":513636,"accession_number":"0000019584-26-000014","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-05-19T14:43:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed say-on-pay fails at annual meeting; 61% votes against","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Non-binding executive compensation proposal rejected: 4,383,683 For vs 6,926,656 Against (61.3% against).","All nine director nominees elected; Patrick P. Grace received 1,946,697 against votes (17.2%).","Ratification of PwC as independent auditor passed with 11,562,294 For (95.7% of votes cast).","Broker non-votes of 769,580 affected say-on-pay and director elections but not ratification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96926,"accession_number":"0000019584-26-000010","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 adjusted EPS $5.65; boosts 2026 guidance to $24.00-$24.75 on VITAS momentum","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $4.84, down 0.4% YoY; adjusted EPS $5.65, up 0.4% YoY.","Revenue $657.5M (+1.6%); VITAS revenue $420.0M (+3.1%); Roto-Rooter revenue $237.5M (-0.9%).","VITAS ADC up 2.2% to 22,723; admissions up 6.9%; adjusted EBITDA ex-Medicare Cap $70.8M (+0.6%), margin 16.8%.","Roto-Rooter adjusted EBITDA $53.5M (-9.6%), margin 22.5% (-218bps); acquired two franchises for $20.6M.","FY 2026 adjusted EPS guidance raised to $24.00-$24.75 from $23.25-$24.25; repurchased 500k shares for $197.7M in Q1."],"consensus_eps_estimate":null,"consensus_eps_actual":4.84,"consensus_revenue_estimate":null,"consensus_revenue_actual":657513000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":96925,"accession_number":"0000019584-26-000008","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-04-13T23:59:59+00:00","items":["1.01","10.1","2.03","9.01"],"status":"ready","headline":"Chemed renews $450M senior secured credit facility for five years","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $450M revolving credit facility includes $100M letters of credit.","Interest rate is SOFR plus tiered spread based on Chemed's leverage ratio.","Facility includes an expansion feature allowing an additional $250M in capacity.","JPMorgan Chase is Administrative Agent; Bank of America, PNC, U.S. Bank also participating.","Credit Agreement dated April 10, 2026; press release issued April 13, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":111296,"accession_number":"0000019584-26-000002","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2026-02-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2025 GAAP EPS down 9%, Roto-Rooter segment weak; guidance for 2026 growth","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $639.3M flat YoY; GAAP diluted EPS $5.48 (-9%), adjusted EPS $6.42 (-6%).","VITAS revenue +1.9% to $418.8M, ADC +1.3% to 22,462, admissions +6%.","Roto-Rooter revenue -3.7% to $220.6M; adjusted EBITDA -21.1%, margin -477bps to 21.5%.","Repurchased 400,000 shares for $174.6M at avg $436.39; $127.3M remaining authorization.","FY2026 adjusted EPS guidance $23.25-$24.25 vs FY2025 $21.55; weighted to H2."],"consensus_eps_estimate":null,"consensus_eps_actual":18.34,"consensus_revenue_estimate":null,"consensus_revenue_actual":2529978000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":127903,"accession_number":"0000019584-25-000004","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3 GAAP EPS falls 10.8% to $4.46; adjusted EPS down 6.6% to $5.27","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $624.9M (+3.1% YoY); VITAS revenue $407.7M (+4.2%), Roto-Rooter $217.2M (+1.1%).","VITAS ADC 22,327 (+2.5%); admissions up 5.6%; Medicare Cap accrual $6.1M vs $2.2M prior year.","Roto-Rooter adjusted EBITDA $49.4M (-12.4%); margin 22.7% vs 26.2% prior year.","Chemed: $129.8M cash, no debt; repurchased 407,500 shares for $180.8M during quarter.","Reiterates FY2025 adjusted EPS guidance $22.00-$22.30, assuming no Florida Medicare Cap."],"consensus_eps_estimate":null,"consensus_eps_actual":12.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1890641000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":144674,"accession_number":"0001562762-25-000181","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-07-29T23:59:59+00:00","items":["2.02","5.02","9.01"],"status":"ready","headline":"Chemed Q2 adjusted EPS $4.27 (-21.9% YoY); cuts FY2025 guidance; VITAS CEO departs","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP EPS $3.57 (-23.2%); adjusted EPS $4.27 (-21.9%); revenue $618.8M (+3.8%).","VITAS adjusted EBITDA margin ex-Medicare cap 16.2% (-163 bps); Florida cap accrual $16.4M.","Roto-Rooter adjusted EBITDA margin 21.8% (-517 bps); revenue +0.6% to $222.6M.","FY2025 adjusted EPS guidance cut to $22.00-$22.30 from $24.95-$25.45; prior year $23.13.","VITAS CEO Nicholas Westfall resigns eff. July 29, 2025; Joel Wherley named successor."],"consensus_eps_estimate":null,"consensus_eps_actual":8.43,"consensus_revenue_estimate":null,"consensus_revenue_actual":1265741000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163076,"accession_number":"0001562762-25-000164","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Chemed projects $18-25M Medicare Cap hit; lowers FY2025 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VITAS expects $18M-$25M Medicare Cap revenue limit for Florida consolidated program (excl. Tallahassee) in 2025 Cap Year.","Lower-than-expected Medicare admissions in Apr-May 2025 and rate differential (2.9% cap increase vs 5.2% reimbursement) caused the cap.","Roto-Rooter experienced unexpected residential demand weakness in Q2 2025; commercial improvement insufficient to offset.","VITAS received Florida CON for Pinellas County on June 20, aiding growth and Cap mitigation for 2026.","Full Q2 2025 results and revised FY2025 guidance due July 29; conference call July 30."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163075,"accession_number":"0001562762-25-000136","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-05-20T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed shareholders elect all director nominees, approve 2025 stock plan and advisory compensation at annual meeting","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All nine director nominees elected; Kevin McNamara received 12,805,746 for vs 203,421 against.","Shareholders approved 2025 Stock Incentive Plan with 11,536,322 for, 1,473,289 against.","Ratified PwC as independent auditor for FY2024 with 13,250,853 for, 365,426 against.","Non-binding advisory vote on executive compensation approved: 11,039,768 for, 1,656,237 against.","Shareholder proposal to reduce special meeting threshold to 10% not presented due to proponent absence."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":163074,"accession_number":"0001562762-25-000088","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-04-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 revenue up 9.8% to $646.9M; GAAP EPS $4.86, adjusted $5.63","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["VITAS net revenue +15.1% to $407.4M; ADC 22,244 (+13.1%); adjusted EBITDA $70.3M (+15.9%).","Roto-Rooter revenue +1.8% to $239.5M but adjusted EBITDA -2.4% to $59.2M; margin down 108 bps.","Cash $173.9M; no debt; repurchased 50k shares for $29.8M at $595.15/share.","Covenant Health contributed ~$12M revenue, $2.6M EBITDA in Q1.","Full-year guidance update deferred to Q2 earnings release in June."],"consensus_eps_estimate":null,"consensus_eps_actual":4.86,"consensus_revenue_estimate":null,"consensus_revenue_actual":646943000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":180982,"accession_number":"0001562762-25-000032","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2024 revenue up 9.2% to $640M; adj. EPS $6.83; guides FY2025 adj. EPS $24.95-$25.45","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $6.02 (+2.0% YoY); adjusted diluted EPS $6.83 (+3.5% YoY).","VITAS net patient revenue $411M (+17.4% YoY); ADC 22,179 (+14.6%).","Roto-Rooter revenue $229M (-2.9% YoY); adjusted EBITDA margin 26.3% (-120 bps).","FY2025 guidance: VITAS revenue growth 10.5%-11.3%, Roto-Rooter revenue growth 2.4%-3.0%.","No debt; $178.4M cash; repurchased 388,235 shares for $212.8M at $548.13/share."],"consensus_eps_estimate":null,"consensus_eps_actual":19.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":2431287000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":197856,"accession_number":"0001562762-24-000241","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-10-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3: rev $606M (+7.4%), adj EPS $5.64; FY2024 adj EPS guidance cut to $23.00-$23.15 on Roto-Rooter weakness","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $5.00 (+1.4%); adjusted diluted EPS $5.64 (+6.0%).","VITAS net patient revenue $391.4M (+17.3%), ADC 21,785 (+15.5%), adjusted EBITDA $73.1M (+33.1%).","Roto-Rooter revenue $214.8M (-6.9%), adjusted EBITDA $56.4M (-15.8%), margin 26.3% (-275 bps).","FY2024 adjusted EPS guidance revised to $23.00-$23.15 (targeting 13.3%-14.0% growth over 2023) due to softer Roto-Rooter results.","Repurchased 100,000 shares for $57.8M at $578.21/share; cash $238.5M, no debt."],"consensus_eps_estimate":null,"consensus_eps_actual":13.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":1791294000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":214043,"accession_number":"0001562762-24-000179","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-07-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 adjusted EPS $5.47 (+34.1% YoY); raises FY2024 guidance to $23.55-$23.80","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $595.9M (+7.6%); GAAP EPS $4.65 (+32.5%); adjusted EPS $5.47 (+34.1%).","VITAS net patient revenue +16.7% to $374.6M; ADC +14.4% to 21,036; adjusted EBITDA +77% to $67.0M.","Roto-Rooter revenue -5% to $221.3M; adjusted EBITDA -9.2% to $59.8M; margin 27.0%.","FY2024 adjusted EPS guidance raised to $23.55-$23.80 (from $23.30-$23.70); VITAS EBITDA margin 19.3%-19.7%.","Repurchased 100k shares for $55.8M; cash $222.9M, no debt; $225.9M remaining buyback authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":8.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1185113000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233266,"accession_number":"0001562762-24-000146","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed annual meeting elects directors, approves PwC and say-on-pay, rejects termination pay proposal","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Kevin McNamara received 13.3M votes for, Patrick Grace 10.3M.","Ratification of PricewaterhouseCoopers as independent auditor for 2024 approved with 13.7M votes for.","Non-binding say-on-pay approved with 11.1M for vs 2.3M against (excluding 657,627 broker non-votes).","Stockholder proposal on termination pay ratification rejected with 1.0M for vs 12.4M against.","Meeting held May 20, 2024; all proposals received majority support except the stockholder proposal."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233265,"accession_number":"0001562762-24-000096","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 2024: Adjusted EPS $5.20 beats; VITAS EBITDA surges 67%, Roto-Rooter down 16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue +5.2% to $589.2M; GAAP EPS $4.24 (+18.4%); Adjusted EPS $5.20 (+21.5%)","VITAS net patient revenue +14% to $354M, ADC up 10.3% to 19,665; adjusted EBITDA +67.2% to $60.7M","Roto-Rooter revenue -5.8% to $235.2M, adjusted EBITDA -15.6% to $60.7M; margin down 299bps","Acquired Covenant Health hospice assets for $85M on Apr 17; no debt, $313.4M cash; bought back 50k shares for $32.3M","Full-year 2024 adjusted EPS guidance reaffirmed at $23.30-$23.70; next update with Q2 results"],"consensus_eps_estimate":null,"consensus_eps_actual":4.24,"consensus_revenue_estimate":null,"consensus_revenue_actual":589233000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":233264,"accession_number":"0001562762-24-000090","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-04-17T23:59:59+00:00","items":["2.01"],"status":"ready","headline":"VITAS completes $85M acquisition of Covenant hospice operations in Florida and Alabama","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Purchased substantially all hospice operations and an assisted living facility from Covenant for $85M in cash.","Hospice markets include Pensacola, Tallahassee, Fort Walton Beach, Panama City in FL and Dothan, Mobile in AL.","Transaction was previously announced on March 13, 2024 and closed effective April 17, 2024.","Purchase funded using cash on-hand; no new debt or equity issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251388,"accession_number":"0001562762-24-000053","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-03-13T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"VITAS to acquire Covenant Care hospice assets for $85M in cash","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["VITAS (Chemed subsidiary) agreed to purchase Covenant Care's hospice operations and an assisted living facility for $85M cash.","Assets span Florida panhandle (Pensacola, Tallahassee, etc.) and Alabama (Dothan, Mobile) markets.","Transaction structured as asset purchase, expected to close in Q2 2024 subject to regulatory approvals.","VITAS Chairman & CEO Nick Westfall highlights cultural alignment and plans to welcome Covenant team members."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251387,"accession_number":"0001562762-24-000036","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 revenue up 7.2% to $585.9M; VITAS adjusted EBITDA +61.6%; FY2024 guidance issued","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $5.90 (+42.9% YoY); adjusted diluted EPS $6.60 (+35.0% YoY).","VITAS net patient revenue $350M (+13.6%), ADC 19,352 (+11%), adjusted EBITDA excl. Medicare Cap $83.3M (+61.6%), margin 23.7%.","Roto-Rooter revenue $235.9M (-1.1%), adjusted EBITDA $64.9M (-6.4%), margin 27.5% (down 154 bps).","FY2024 adj. EPS guidance $23.30-$23.70 vs 2023 adj. EPS $20.30; VITAS rev growth 9-9.8%, Roto-Rooter rev growth 3.5-4%.","Cash $264M, no debt; repurchased 79,512 shares for $46M at $579.09 per share."],"consensus_eps_estimate":null,"consensus_eps_actual":17.93,"consensus_revenue_estimate":null,"consensus_revenue_actual":2264417000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":251386,"accession_number":"0001562762-24-000015","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2024-02-01T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemed CFO David P. Williams transitions to CEO advisor role with new equity grant and salary","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Williams resigned as EVP and CFO, now serves as advisor to CEO effective Jan 29, 2024.","Granted 6,424 Performance Share Units vesting 100-200% based on 3-year TSR vs peer companies (2024-2026).","Monthly salary set at $38,750; eligible for general employee benefits; employment terminable on 12 months' notice.","Prior employment agreement and Change in Control Severance Plan benefits terminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268945,"accession_number":"0001562762-23-000442","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-12-18T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Chemed appoints Michael Witzeman as CFO effective Jan 1, 2024, succeeding retiring David P. Williams","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Michael Witzeman appointed CFO, effective January 1, 2024, replacing David P. Williams who is retiring.","Witzeman is currently Chemed's Vice President, Controller, and principal accounting officer.","He joined Chemed in 2005; previously Senior Manager at Deloitte & Touche; holds CPA, BBA, MBA.","No other officer changes or compensation adjustments disclosed in the filing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268944,"accession_number":"0001562762-23-000398","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-11-03T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemed CFO David P. Williams to retire Dec 31, 2023; will stay in transition role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Executive VP and CFO David P. Williams will retire effective December 31, 2023, after over 30 years at Chemed.","Williams joined Chemed in 1990, served as CFO since March 2004 and Executive VP since August 2007.","He will continue to provide guidance to the executive team and Board during the transition period.","No replacement CFO has been announced as of the filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":268943,"accession_number":"0001562762-23-000378","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-10-25T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3 revenue +7.2% to $565M; raises FY2023 adjusted EPS guidance to $19.82-$20.02","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $4.93 (+30.4% YoY); adjusted diluted EPS $5.32 (+24.9%).","VITAS net patient revenue $334M (+12.5%), ADC 18,859 (+9.4%), adjusted EBITDA margin 16.5% (+441 bps).","Roto-Rooter revenue $231M (+0.4%), adjusted EBITDA $66.9M (-3.7%), margin 29.0% (-124 bps).","Full-year adjusted EPS guidance raised to $19.82-$20.02 from $18.72-$18.92, includes $1.18/sh retention costs.","Ended quarter with $173M cash, no debt; repurchased $14.3M in shares at avg $504.07."],"consensus_eps_estimate":null,"consensus_eps_actual":12.02,"consensus_revenue_estimate":null,"consensus_revenue_actual":1678505000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":286041,"accession_number":"0001562762-23-000290","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-07-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 revenue up 4.2% to $554M; adjusted EPS $4.71 down 2.7% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $3.51; adjusted diluted EPS $4.71 (down 2.7% YoY).","VITAS net revenue $321M (+7.8%); ADC 18,392 (+6.2%); admissions 15,611 (+5.9%).","Roto-Rooter revenue $233M (-0.2%); adjusted EBITDA $65.9M (-4.5%); margin 28.3%.","No debt; $160M cash; $405M undrawn credit facility; repurchased 25,000 shares for $13.4M.","FY2023 adjusted EPS guidance $19.90-$20.10 vs 2022's $19.75."],"consensus_eps_estimate":null,"consensus_eps_actual":7.09,"consensus_revenue_estimate":null,"consensus_revenue_actual":1113973000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305909,"accession_number":"0001562762-23-000250","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-05-16T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed shareholders re-elect all 10 directors, ratify PwC, approve executive compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All 10 director nominees elected; Patrick P. Grace and George J. Walsh III received ~3.3M and 2.1M against votes.","Ratification of PricewaterhouseCoopers LLP as independent auditor for 2023 approved with 13.7M for vs 436.8K against.","Non-binding advisory vote on executive compensation approved: 10.4M for, 3.0M against, 35.7K abstain.","Stockholder proposal on termination pay (say-on-golden-parachutes) rejected: 6.5M for, 6.9M against.","Board set frequency of say-on-pay votes at one year; Eileen McCarthy appointed to Compensation/Incentive Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":305908,"accession_number":"0001562762-23-000174","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 revenue up 5.6% to $560M; adjusted EPS $4.82 (+0.6%)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS $3.58; adjusted diluted EPS $4.82, up 0.6% YoY.","VITAS net patient revenue $310M (+3.8%), ADC 17,830 (+3.0%), but adjusted EBITDA margin fell 234 bps to 15.1% due to sequestration and hiring.","Roto-Rooter revenue $250M (+7.9%), adjusted EBITDA $71.8M (+9.0%), margin 28.8% (+29 bps).","Cash $58.1M, debt $21.3M; $405M undrawn revolver.","Management will provide updated 2023 guidance in June 2023 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":3.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":560157000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":325192,"accession_number":"0001562762-23-000053","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2023-02-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2022 adjusted EPS $5.39 (+2.7% YoY); guides 2023 adjusted EPS $20.75-$21.10","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $547M (+1.0% YoY); GAAP diluted EPS $4.13; adjusted diluted EPS $5.39.","VITAS net patient revenue $308M (-2.5%); ADC 17,434 (-2.8%); admissions -8.7%; adjusted EBITDA margin 19.8% (-189bps).","Roto-Rooter revenue $239M (+6.1%); adjusted EBITDA $69.3M (+11.4%); margin 29.0% (+138bps).","2023 guidance: VITAS revenue +6-7%, ADC +3.5-4%; Roto-Rooter revenue +5-5.5%; adjusted EPS $20.75-$21.10.","Share repurchases: 25,000 shares for $13.0M in Q4; $88M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":16.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":2134963000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342986,"accession_number":"0001562762-22-000491","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Chemed amends bylaws to enhance stockholder proposal and director nomination procedures","summary_kind":"llm","event_type":"other","confidence":"medium","bullets":["Amendments require additional disclosures and representations regarding stockholder nominations and proposals.","Stockholders must provide reasonable documentary evidence 5 business days before meeting of compliance with Rule 14a-19 (universal proxy).","Stockholders must notify Chemed if they no longer intend to solicit proxies after submitting a nomination notice.","Presiding officer powers clarified to determine compliance of business proposals and director nominations with the bylaws."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342984,"accession_number":"0001562762-22-000433","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K/A","filed_at":"2022-11-07T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Chemed appoints director John M. Mount, Jr. to Audit Committee","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["John M. Mount, Jr. appointed to Chemed Board effective August 5, 2022.","On November 4, 2022, Board determined Mr. Mount is independent.","Mr. Mount appointed to Audit Committee."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":342985,"accession_number":"0001562762-22-000404","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-10-31T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3 revenue down 2.3% to $526M; raises 2022 adjusted EPS guidance to $19.60-$19.70","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["GAAP diluted EPS of $3.78; adjusted diluted EPS of $4.74, down 6.3% YoY.","VITAS net revenue fell 6.6% to $297M; ADC down 4.4% to 17,242; admissions down 16.6%.","Roto-Rooter revenue rose 3.9% to $230M; adjusted EBITDA margin improved 50bps to 30.2%.","Company repurchased 50,000 shares for $23.9M at avg cost $477.68; $101M authorization remaining.","2022 adjusted EPS guidance raised to $19.60-$19.70 from $19.30-$19.50; VITAS revenue forecast down 4.5%-5%."],"consensus_eps_estimate":null,"consensus_eps_actual":12.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":1588309000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359547,"accession_number":"0001562762-22-000343","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-08-05T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Donald E. Saunders retires; John M. Mount Jr. appointed to Chemed board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Donald E. Saunders retired from Chemed's Board effective 5:00 ET August 5, 2022.","John M. Mount Jr., Coca-Cola's NA Sports & Entertainment Marketing Team Lead, appointed to the Board same date.","Mount will receive standard non-employee director compensation; no committee assignments yet determined.","No related-person transactions or arrangements existed between Mount and any other person.","Mount's appointment fills the vacancy created by Saunders' retirement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":359546,"accession_number":"0001562762-22-000302","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 adj EPS $4.84, raises FY22 guidance low-end to $19.30; Roto-Rooter revenue +6%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $531M, down 0.2% YoY; GAAP diluted EPS $4.40 (+25.4%); adjusted diluted EPS $4.84 (+5.2%).","VITAS revenue $298M (-4.5%); ADC 17,315 (-3.8%); admissions -12.5%; adj EBITDA margin 16.7% (-78bps).","Roto-Rooter revenue $233M (+6.0%); adj EBITDA $69.0M (+7.4%); margin 29.6% (+39bps).","FY2022 adjusted EPS guidance raised to $19.30-$19.50 from $19.10-$19.50; VITAS rev. decline 4.5-5.0%, Roto-Rooter growth 5.5-5.7%.","Repurchased 100,000 shares for $49.9M at avg $498.61; entered new $550M credit agreement in June."],"consensus_eps_estimate":null,"consensus_eps_actual":8.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1061837000.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378312,"accession_number":"0001562762-22-000286","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-06-29T23:59:59+00:00","items":["1.01","10.1","2.03","9.01"],"status":"ready","headline":"Chemed enters $550M amended credit facility with $450M revolver and $100M term loan","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Five-year $450M revolving credit facility and five-year $100M term loan.","Interest rate is SOFR plus a tiered rate based on Chemed's leverage ratio.","Includes an accordion feature allowing up to $250M in additional capacity.","JPMorgan Chase acted as Administrative Agent and Joint Lead Arranger."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378311,"accession_number":"0001562762-22-000254","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-05-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Chemed shareholders elect all director nominees, approve 2022 stock incentive plan","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All 10 director nominees elected; Joel F. Gemunder received 8.75M for, 3.92M against, 517k abstain.","2022 Stock Incentive Plan approved with 11.17M for, 2.02M against, 8,572 abstain.","Ratification of PricewaterhouseCoopers as independent auditor for FY2022 approved with 13.13M for.","Non-binding advisory vote on executive compensation approved with 11.81M for, 1.37M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":378310,"accession_number":"0001562762-22-000191","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q1 2022: EPS up 7.9% on adjusted basis; VITAS revenue down 5.3%, Roto-Rooter up 9.4%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $531M (+0.6% YoY); GAAP diluted EPS $4.22 (+5.2%); adjusted diluted EPS $4.79 (+7.9%).","VITAS net patient revenue $299M (-5.3%), ADC 17,313 (-4.1%), admissions 16,530 (-8.9%).","Roto-Rooter revenue $231M (+9.4%); net income excl. discrete items $46.4M (+18.0%); adjusted EBITDA margin 28.5% (+160 bps).","Chemed repurchased 57,500 shares for $27.4M at avg. cost $475.71; remaining auth. ~$175M.","Management to provide updated 2022 earnings guidance in June 2022 earnings release."],"consensus_eps_estimate":null,"consensus_eps_actual":4.22,"consensus_revenue_estimate":null,"consensus_revenue_actual":530549000.0,"consensus_period":"2022-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":396592,"accession_number":"0001562762-22-000054","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2022-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q4 2021 adj EPS $5.25, up 2.3%; VITAS revenue down 4.8%; issues mixed 2022 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated Q4 revenue $541M (+1.4%); GAAP diluted EPS $4.81; adjusted diluted EPS $5.25 (+2.3%).","VITAS net revenue $316M (-4.8%), ADC 17,935 (-4.2%), admissions down 9.5%; adjusted EBITDA margin 21.7% (-179 bps).","Roto-Rooter revenue $225M (+11.8%); adjusted EBITDA $62.2M (+14.2%); margin 27.7% (+58 bps).","2022 guidance: adjusted EPS $19.10-$19.50 (vs 2021 $19.33); VITAS revenue down 1.5-2.5%; Roto-Rooter revenue growth 8-9.5%.","Q4 share repurchases: 495,529 shares for $246M; $202M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":16.85,"consensus_revenue_estimate":null,"consensus_revenue_actual":2139261000.0,"consensus_period":"2021-FY","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":415555,"accession_number":"0001562762-21-000377","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2021-10-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q3 adj. EPS $5.06 (+4.1%), revenue $539M (+2%); FY21 guidance raised to $19.00-$19.20","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Repurchased 350,000 shares for $164M; $148M remaining authorization; no long-term debt.","VITAS revenue -5.8% to $317M, ADC -5.3%; Roto-Rooter revenue +15.7% to $221M.","Roto-Rooter adjusted EBITDA margin 29.7% (+266 bps); VITAS margin 19.0% (-146 bps).","Full-year 2021 adjusted EPS guidance raised to $19.00-$19.20 from prior $17.00-$17.50.","Adjusted diluted EPS of $5.06 beats prior-year $4.86; GAAP EPS $4.55."],"consensus_eps_estimate":null,"consensus_eps_actual":12.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":1598283000.0,"consensus_period":"2021-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":433190,"accession_number":"0000019584-21-000011","cik":19584,"company_name":"CHEMED CORP","ticker":"CHE","form_type":"8-K","filed_at":"2021-07-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Chemed Q2 adj. EPS $4.60 (+4.3% YoY); Roto-Rooter revenue +26.1%; full-year guidance raised to $18.20-$18.50","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Consolidated revenue $532M (+6.0%); GAAP diluted EPS $3.51 (-29.9%); adjusted diluted EPS $4.60 (+4.3%).","VITAS net patient revenue $312M (-4.7%); ADC 17,995 (-6.3%); adjusted EBITDA margin ex-Medicare Cap 17.4% (-430bps).","Roto-Rooter revenue $220M (+26.1%); adjusted EBITDA margin 29.2% (+236bps); residential +23.7%, commercial +31.8%.","Full-year 2021 adjusted EPS guidance raised to $18.20-$18.50 from prior $17.00-$17.50; no debt, $92M cash.","Company repurchased 250,000 shares for $122M during Q2; $312M remaining authorization."],"consensus_eps_estimate":null,"consensus_eps_actual":7.52,"consensus_revenue_estimate":null,"consensus_revenue_actual":1059616000.0,"consensus_period":"2021-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":5832773492.735898,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}